This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Mark R. Goldstein, MD
Crozer-Chester Medical Center Upland, Pa

JAMA. 1997;278(8):633.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Dr Schrott and colleagues¹ suggest that women with established coronary heart disease have been undertreated for elevated low-density lipoprotein cholesterol (LDLC) levels based on screening data from the Heart and Estrogen/ Progestin Replacement Study (HERS). However, evidencebased medicine suggests the women were adequately treated.

At screening, nearly half of the participants of the trial were taking cholesterol-lowering medication. The suggestion that women were undertreated was based on the failure of a majority of the HERS cohort to have achieved LDL-C goals set by the National Cholesterol Education Program (NCEP) adult treatment panel in 1988² and 1993.³ Those goals were derived from trials involving men and extrapolated to women. The screening for HERS ended in September 1994, before evidence-based medicine suggested that women might benefit from cholesterol lowering. The Scandinavian Simvastatin Survival Study (4S)⁴ and the Cholesterol and Recurrent Events (CARE) trial⁵ were . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?